The detection of oxycodone in meconium specimens

Area of Science:

• Clinical Chemistry
• Toxicology
• Neonatal Health

Background:

• Oxycodone (OxyContin) abuse is a significant public health concern, with potential risks to neonates exposed in utero.
• Standard screening immunoassays show limited cross-reactivity with oxycodone, potentially leading to false negatives.
• Accurate detection of neonatal drug exposure is crucial for appropriate medical care.

Purpose of the Study:

• To develop and validate a novel assay for the accurate determination of oxycodone in meconium.
• To improve the detection sensitivity and specificity for neonatal oxycodone exposure.
• To establish a reliable method for routine laboratory use.

Main Methods:

• Development of a direct ELISA microplate immunoassay for oxycodone screening.
• Confirmation of positive results using electron impact gas chromatography-mass spectrometry (GC-MS).
• Validation of the combined immunoassay and GC-MS protocol for meconium analysis.

Main Results:

• The direct ELISA demonstrated low cross-reactivity with morphine, enhancing specificity.
• The combined ELISA-GC-MS method provides accurate and sensitive detection of oxycodone.
• The developed assay is suitable for routine clinical laboratory application.

Conclusions:

• A novel, reliable assay combining direct ELISA and GC-MS has been established for oxycodone detection in meconium.
• This method improves the identification of neonatal exposure to oxycodone, addressing limitations of standard screening.
• The assay's routine implementation supports better clinical management of infants exposed to maternal drug use.